Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early proactive infliximab TDM in pediatric IBD
2024-517759-11-00Phase 4Authorised
- Sponsor
- IRCCS Burlo Garofolo
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of infliximab in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis (2 arms), sponsored by IRCCS Burlo Garofolo. Primary endpoint: Primary composite endpoint. Planned start Oct 2024; status: authorised.
02
Drugs
infliximab
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on 2024-517759-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517759-11-00.